Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
ApexOnco Front Page
Recent articles
Adverse events will be closely watched when full data are reported.
Summit gatecrashes ASCO, but Harmoni shows no OS benefit and a large patient overlap.
The second line shows no respite for Merck & Co's ROR1-targeting ADC.
Crunch time approaches for UroGen.
The combined company's MALT1 inhibitor has started phase 1.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Meanwhile, Pfizer reckons it's found the right dose for its KAT6.
